Overview

Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects

Status:
Completed
Trial end date:
2020-02-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the clinical efficacy and safety of ISV-305 (Dexamethasone in DuraSite® 2) compared to Vehicle in the treatment of subjects with active, symptomatic Blepharitis.
Phase:
Phase 3
Details
Lead Sponsor:
InSite Vision
Sun Pharma Global FZE
Treatments:
Dexamethasone